Genmab
GMAB
174 hedge funds and large institutions have $1.34B invested in Genmab in 2020 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 65 increasing their positions, 42 reducing their positions, and 21 closing their positions.
684% more call options, than puts
Call options by funds: $4.74M | Put options by funds: $604K
152% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 21
109% more capital invested
Capital invested by funds: $640M → $1.34B (+$699M)
55% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 42
23% more funds holding
Funds holding: 142 → 174 (+32)
14.35% more ownership
Funds ownership: 43.77% → 58.12% (+14%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$70.8M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$33.8M |
| 3 |
Morgan Stanley
New York
|
+$28.9M |
| 4 |
Renaissance Technologies
New York
|
+$26M |
| 5 |
BlackRock
New York
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
-$45M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$13.4M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$12.1M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$7.8M |
GMAB Hedge Fund Activity: Q2 2020 in Review
174 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2020, worth a combined $1.34B — up 109% from $640M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new GMAB positions and 21 closed out — a net gain of 32 holders — while 65 added to existing stakes and 42 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $70.8M. The largest seller was Lazard Asset Management, cutting an estimated $45M.
- 174 institutional investors held Genmab (GMAB) as of Q2 2020, up from 142 in Q1 2020.
- Funds reported $1.34B of Genmab stock for Q2 2020, up 109% quarter-over-quarter.
- 53 funds opened new Genmab positions in Q2 2020 and 21 closed out, a net change of +32 holders.
- The largest Genmab buyer in Q2 2020 was Capital International Investors, an estimated $70.8M added.
- The largest Genmab seller in Q2 2020 was Lazard Asset Management, an estimated $45M sold.
Based on aggregated 13F filings for Q2 2020.